Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ceftolozane-tazobactam

ceftolozane-tazobactam

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ceftolozane-tazobactam

8 trials tracked of ceftolozane-tazobactam: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 151 citations.

8Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 3 Phase 1 2
  1. Phase 3 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) Completed · 151 cited
  2. Phase 4 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Completed · 49 cited
  3. Phase 3 Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) Completed · 20 cited
  4. Phase 2 MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Completed
  5. Phase 2 MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) Completed
  6. Phase 2 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid Completed
Show 2 more trials
  1. Phase 1 Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) Completed
  2. Phase 1 Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ceftolozane-tazobactam associated with higher clinical cure rates in multidrug-resistant Pseudomonas aeruginosa infections
Infectious Disease Meta-analysis
Ceftolozane-tazobactam associated with higher clinical cure rates in multidrug-resistant Pseudomonas aeruginosa infections Comparing Two Different Antibiotics for Treating Tough Pseudomonas Aeruginosa Infections
Researchers compared ceftolozane-tazobactam and ceftazidime-avibactam for treating multidrug-resistant and difficult-to-treat Pseudomonas ae…
Doctors are comparing two powerful antibiotics to see which one works best against hard-to-treat bacterial infections.
Sep 11, 2026
Pharmacokinetic and clinical data inform therapeutic selection for difficult to treat Pseudomonas aeruginosa CNS infections
Allergy & Immunology Sys. Review
Pharmacokinetic and clinical data inform therapeutic selection for difficult to treat Pseudomonas aeruginosa CNS infections New strategies help treat drug resistant brain infections
This narrative review evaluates the feasibility of various antimicrobial agents, including ceftolozane-tazobactam, ceftazidime-avibactam, az…
Doctors are finding new ways to treat serious brain infections caused by bacteria that have become hard to kill with standard medicine.
Frontiers Aug 4, 2026
Ceftolozane-tazobactam shows comparable efficacy to ceftazidime-avibactam but lower risk of recurrent infection
Infectious Disease Meta-analysis
Ceftolozane-tazobactam shows comparable efficacy to ceftazidime-avibactam but lower risk of recurrent infection New analysis shows lower risk of repeat infections for patients
This systematic review and meta-analysis of 3,361 patients with drug-resistant Pseudomonas aeruginosa infections found no significant differ…
A new review of 3,361 patients found that one specific antibiotic may help prevent recurring infections in those with drug-resistant bacteri…
Aug 3, 2026
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections
Infectious Disease Meta-analysis
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections Which antibiotic works better for dangerous drug-resistant infections?
A meta-analysis of 10 observational studies including 1409 patients with drug-resistant P.
Two powerful new antibiotics show equal survival rates for patients fighting dangerous, drug-resistant infections.
Apr 2, 2026